An Update on Follicular Lymphoma

MEET THE EXPERTS ALL PROGRAMMES DEVELOPED COLLABORATIONS CONTACT

An Update on Follicular Lymphoma

Dr. Matthew Matasar provides an update on follicular lymphoma Dr. Matthew Matasar provides an update on follicular lymphoma

Dr Matthew J. Matasar

Watch the video and download the slides

Dr Matthew J. Matasar

Medical Oncologist and Haematologist

Rutgers Cancer Institute of New Jersey

United States (US)

Biography Disclosures

Dr Matthew J. Matasar

Medical Oncologist and Haematologist

Rutgers Cancer Institute of New Jersey

United States (US)

Dr Matthew Matasar is a board-certified medical oncologist/hematologist, who received his undergraduate and medical degrees from Harvard University. His internal medicine training was completed at Columbia Presbyterian, where he earned a Master’s in biostatistics, while serving as Chief Resident. His fellowship training was in medical oncology at Memorial Sloan Kettering Cancer Center, where he subsequently joined faculty on the Lymphoma and Adult BMT services. Dr Matasar is also the Director of the Lymphoma Survivorship Clinic, where he focuses on the management of long-term survivors of Hodgkin and non-Hodgkin lymphoma. As the Section Head for Aggressive B-cell Lymphomas, his research is focused on improving outcomes in relapsed but curable patients using novel therapies. He is the Medical Director at MSK Bergen, directing a team of expert oncologists in the delivery of cutting-edge care across cancer service lines to patients at the free-standing outpatient center in Montvale, New Jersey.

Dr Matthew J. Matasar has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Bayer Pharmacyclics, Genentech, GlaxoSmithKline, Immunovaccine Tech, Janssen, Juno Theraputics, Merck, Roche Rocket Medical, Seattle Genetics, Teva and Takeda.

time E-learning | open 5 min |accreditation: EACCME | 2019

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

download resources

DOWNLOAD THE SLIDES

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

This course has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) and ECMEC® is available. Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

LYMPHOMA & MYELOMA CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer and from Karyopharm Therapeutics.

Other programmes of interest

Dr Matthew J. Matasar

4 min

Update From ASH 2022

Dec 2022

Asst. Prof. Hans Lee

2 min

Update from ASCO 2022 - Myeloma

May 2022

Dr. Alexander Lesokhin and Dr. Maria Victoria Mateos

Assoc. Prof. María Victoria Mateos

Dr Alexander M Lesokhin

Podcast

20 min

Podcast: Choosing the Best Treatment Regimen in Patients with Hig...

Mar 2022

Dr Matthew J. Matasar

5 min

Lymphoma Update from ASH 2021

Dec 2021

Translating the biology of diffuse large b cell lymphoma into treatment The Oncologist

Dr Matthew J. Matasar

Dr Massimo Magagnoli

Prof. Alexey V Danilov

5 min

DLBCL Review Paper Published in The Oncologist

Jan 2022

Dr Claudio Cerchione

10 min

Update from the 2021 Autumn Congresses in Multiple Myeloma

Nov 2021

Assoc. Prof. Karthik Ramasamy

Assoc. Prof. Joshua Richter

Podcast

25 min

Podcast: Choosing the Best Treatment Regimen in RRMM (Episode 2 o...

Oct 2021

Dr. Joshua Richter and Dr. Karthik Ramasamy

Assoc. Prof. Karthik Ramasamy

Assoc. Prof. Joshua Richter

Podcast

20 min

Podcast: Choosing the Best Treatment Regimen in NDMM (Episode 1 o...

Oct 2021

Assoc. Prof. Tycel Phillips

5 min

Highlights in Lymphoma

Jul 2021

Update from ASCO and EHA 2021 on Multiple Myeloma - LYMPHOMA & MYELOMA CONNECT

Asst. Prof. Hans Lee

5 min

Update from ASCO and EHA 2021 on Multiple Myeloma

Jun 2021

Assoc. Prof. María Victoria Mateos

5 min

Highlights in Multiple Myeloma

Jun 2021

Prof. Stefano Luminari

5 min

Update from ASH 2018 #2

2018

Other programmes developed by Dr Matthew J. Matasar

Dr Matthew J. Matasar

Medical Oncologist and Haematologist

Rutgers Cancer Institute of New Jersey

United States (US)

Dr Matthew J. Matasar

4 min

Update From ASH 2022

Dec 2022

Dr Matthew J. Matasar

5 min

Lymphoma Update from ASH 2021

Dec 2021

Dr Matthew J. Matasar

Dr Massimo Magagnoli

Prof. Alexey V Danilov

5 min

DLBCL Review Paper Published in The Oncologist

Jan 2022

LYMPHOMA CONNECT review paper published in The Oncologist - LYMPHOMA & MYELOMA CONNECT

Prof. Alexey V Danilov

Assoc. Prof. Loretta Nastoupil

Dr Matthew J. Matasar

And others...

0 min

Follicular Lymphoma Review Paper Published in The Oncologist

2019

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.